SCHEDULE 13G/A: Foresite Capital and James Tananbaum Disclose 9.2% Passive Stake in Lyell Immunopharma

Foresite Capital entities and managing member James Tananbaum have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 9.2% of Lyell Immunopharma, Inc.'s common stock as of March 31, 2025.

Summary

• Foresite Capital Fund IV, L.P. (FCF IV) beneficially owns 16,007,999 shares, representing 5.4% of Lyell Immunopharma, Inc.'s common stock.
• Foresite Capital Management IV, LLC (FCM IV), as the general partner of FCF IV, is deemed to have sole voting and dispositive power over FCF IV's shares.
• Foresite Capital Fund V, L.P. (FCF V) beneficially owns 8,133,047 shares, representing 2.8% of Lyell Immunopharma, Inc.'s common stock.
• Foresite Capital Management V, LLC (FCM V), as the general partner of FCF V, is deemed to have sole voting and dispositive power over FCF V's shares.
• Foresite Capital Opportunity Fund V, L.P. (FCF Opp V) beneficially owns 3,020,846 shares, representing 1.0% of Lyell Immunopharma, Inc.'s common stock.
• Foresite Capital Opportunity Management V, LLC (FCM Opp V), as the general partner of FCF Opp V, is deemed to have sole voting and dispositive power over FCF Opp V's shares.
• James Tananbaum, as the managing member of FCM IV, FCM V, and FCM Opp V, is deemed to have sole voting and dispositive power over an aggregate of 27,161,892 shares, representing 9.2% of the outstanding common stock.
• The percentage ownership is calculated based on 295,228,868 shares of Lyell Immunopharma, Inc. Common Stock outstanding as of March 6, 2025, as reported in the Issuer's Form 10-K filed on March 11, 2025.
• The securities were acquired and are held for passive investment purposes, not for changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G Amendment) disclosing beneficial ownership. It is factual and does not contain positive or negative performance indicators, forward-looking statements, or strategic shifts. Its sentiment is neutral, reflecting a standard compliance disclosure.

Future Outlook

NA

Industry Context

This filing indicates continued significant passive investment by a prominent healthcare and life sciences investment firm, Foresite Capital, in Lyell Immunopharma, a biotechnology company. Such substantial institutional holdings are common in the biotech sector, where long-term capital is often required for research and development.

Related Party Transactions

• Under certain circumstances, the partners or members of Foresite Capital's funds and management entities may be deemed to have the right to receive dividends or proceeds from the sale of Lyell Immunopharma shares held by these entities.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant, passive institutional investor (Foresite Capital) maintains a substantial stake in Lyell Immunopharma, which may be viewed positively as a sign of investor confidence.

Key Dates

Keywords

Lyell Immunopharma, Foresite Capital, James Tananbaum, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Biotechnology, Investment Fund